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Remodeling of extracellular matrix (ECM) is a key event in
progression and reversal of kidney disease. This process
results from synthesis of ECM components and their
degradation, mostly by matrix metalloproteinases (MMPs).
However, because of both the multiplicity of their targets
that include non-matrix substrates, and the complexity of
their regulation, MMPs may exert different, and even
opposite, effects during the different phases of the evolution
of kidney diseases. The major challenge with future
therapeutic interventions will be to accomplish temporal
control of MMP activity. In addition to MMPs, enzymes that
stabilize ECM (transglutaminase) and cell receptors for ECM
components including integrins and discoidin domain
receptor-1 (DDR1), play an important role in the cell response
to matrix remodeling. Novel therapeutic approaches aimed
at targeting transglutaminase and ECM receptors, particularly
DDR1, are a promising option provided that specific and safe
pharmacological inhibitors be developed. These therapies
together with pharmacological agents controlling MMP
activity, given in appropriate windows of the course of
kidney diseases may represent a useful adjunct to blockers
of the renin–angiotensin system.
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The increasing incidence of diabetes, obesity, and vascular
diseases has led to an epidemic of chronic kidney disease
(CKD). Regardless of the primary etiology, most forms of
CKD tend to progress to end-stage glomerulosclerosis and
tubulointerstitial fibrosis, resulting in loss of functional
nephrons. Progressive fibrosis is a common process pro-
moted by epithelial remodeling, inflammation, fibroblast
activation, and reorganization of cellular interactions with
the extracellular matrix (ECM). During this process, there is a
desequilibrium between the increased synthesis of ECM
components and decreased ECM degradation mostly by
matrix metalloproteinases (MMPs) that are under the control
of specific inhibitors (tissue inhibitors of metalloproteinases
(TIMPs)).
Reversal of CKD have been achieved in experimental
models following therapy with renin–angiotensin system
blockers.1 Reversal requires destabilization and degradation
of the accumulated ECM by MMPs, together with decreased
synthesis of ECM components.2 These results, however,
contrast with large-scale human studies that observed at best
a slower rate of decrease of renal function, because the
diagnosis of kidney disease is much delayed in most human
nephropathies, and pathogenesis is probably more complex
in humans than in animals.
By their ability to degrade ECM, MMPs are at the
crossroads of disease progression and regression. However, it
would be simplistic to consider these enzymes only as ‘good
guys’. Owing to the multiplicity of their targets including
non-matrix substrates and the complexity of their regulation
that account for a variety of biological effects, MMP-resulting
effects may be different and even opposite during the
different phases of the evolution of nephropathies.
In addition, the capacity of MMPs to act on and degrade
ECM components also depends on the stabilization and/or
binding of ECM to cell membrane through integrin and non-
integrin receptors. Recent studies indicate that this receptor-
mediated interaction is not as ‘silent’ as initially thought but
can trigger signaling pathways that may lead to important cell
phenotypic changes. By remodeling ECM, MMPs probably
have a substantial impact on these processes.
This mini-review will focus on the role of MMPs and
matrix receptors in kidney disease progression and reversal
and will tentatively provide clues to future therapeutic
interventions.
ROLE OF MMPS IN DISEASE PROGRESSION AND REVERSAL
The family of MMPs and the kidney
Matrix metalloproteinases were discovered more than 40
years ago, by their ability to degrade rigid rods of collagen
during metamorphosis in tadpoles. This activity turned out
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to be due to interstitial collagenase, which is the first member
of an ever-growing large family of zinc-requiring enzymes,
which also include gelatinases, stromelysins, matrilysins
macrophage elastase, and membrane-type MMPs. MMPs
degrade synergistically all components of the ECM in a
concerted manner.3
In the kidney, gelatinases (MMP-2, -9) are assumed to be
important players because they cleave basement membrane
(BM) components, mostly type-IV collagen.3 BMs are known
to play a key role in induction, progression, and repair
of kidney disease. Indeed, BM damage is a major event
in crescentic glomerulonephritis, Alport’s syndrome, and
epithelial-to-mesenchymal transition (EMT). In addition,
MMP-9 can cleave type-V collagen, aggrecan, and elastin,
whereas MMP-2 can degrade fibronectin and laminin. Unlike
MMP-2, which is mostly constitutively expressed, MMP-9
has a restricted pattern of expression and is highly regulated
by cytokines and growth factors. MMP-2 and MMP-9 also
differ by their mode of activation because pro-MMP-2
is activated at the cell surface by a membrane-type
MMP, whereas the activation of pro-MMP-9 mostly occurs
through plasmin(ogen)-dependent and plasmin(ogen)-
independent mechanisms. Both MMP-2 and MMP-9 also
have the ability to form proenzyme complexes with
TIMPs. Alpha 2-macroglobulin, tissue factor protease
inhibitor-2, and thrombospondins are natural inhibitors of
gelatinases.
Role of MMPs in ECM remodeling
Matrix homeostasis in normal tissues is a balance between
matrix production and degradation. The excessive matrix
accumulation seen in fibrotic kidney results from a
combination of overproduction of matrix components and
defective degradation. About 30 matrix proteins have been
characterized as substrates of MMP in vitro. Nonetheless, the
dogma that the main role of the MMPs is to cleave matrix
proteins is still controversial, for at least three reasons. First,
only two matrix proteins, collagen type-IV and aggrecan,
were shown to be cleaved in vivo.3 Second, except for the
MT1-MMP-deficient mice, which develop fibrosis of soft
tissues, other MMP knockout mice do not spontaneously
develop tissue fibrosis, although this may be explained in
some cases by redundancy, for example, compensation by
other MMPs.3 Even more, transgenic mice overexpressing
MMP-2 display fibrotic lesions.4 Third, no side effects relative
to connective tissue were reported in tumor treatment studies
using MMP inhibitors. These results raise the following
question: can MMP really help prevent or resolve fibrosis in
pathological conditions?
On the one hand, MMP-9 usually is considered as an
antifibrotic enzyme because it cleaves type-IV collagen and
particularly denatured collagens that result from the action of
interstitial collagenases. On the other hand, MMP9 can also
be viewed as a profibrotic agent because it activates tumor
growth factor-b (TGF-b) and endothelin-1, and the degrada-
tion of type-IV collagen may favor EMT.3 Furthermore,
MMP-2 was found to be necessary and sufficient to induce
tubular cell EMT in vitro.5 The role of MMP-2 and MMP-9
in renal disease progression in vivo has recently been investigated
by using pharmacological agents and knockout mice.
The case of nephroangiosclerosis and vascular remodeling
Hypertension and renal failure were induced by inhibiting
nitric oxide synthesis in rats.2 After 1 month of hypertension,
animals displayed a decline of renal function, an exaggerated
gene and protein expression of TGF-b, collagen-I, and
collagen-IV within the renal vasculature, and an abnormal
accumulation of ECM in glomeruli. These structural and
functional alterations were accompanied by increased
activities of MMP-2 and MMP-9. Administration of an
angiotensin-II (AngII) receptor antagonist rapidly decreased
collagen-I, collagen-IV, and TGF-b genes and proteins,
without affecting activities of MMP-2 and MMP-9. These
cellular alterations were accompanied by a gradual regression
of glomerulosclerosis and restoration of renal function; after
1 month, all functional and structural parameters of kidney
were normalized.
The mechanism of regression appeared to be dual:
inhibition of collagen synthesis due to AT1 blockade and
activation of MMP that is probably associated with the
degree of fibrosis. These results are corroborated by the
observation that most often in experimental models and
human diseases, fibrosis is usually accompanied by sustained
increase of MMP expression. The upregulated MMP expres-
sion presumably reflects cellular compensatory mechanisms
aimed at limiting the rate of matrix accumulation. It is likely
that integrins and other ECM receptors inform the cells that
ECM is accumulating in the cellular microenvironment, thus
triggering a cascade of events that lead to sustained MMP
synthesis and activity (see below).
Surprisingly, in MMP9-deficient mice that have a baseline
blood pressure similar to that of wild-type mice, the systolic
pressure increment in mice treated with L-NAME (which
inhibits nitric oxide synthase) or with Ang II was more
important in MMP-9/ animals than in the wild-type
animals. In wild-type mice treated with AngII (1 mg/kg/min,
10 days) plus 5% NaCl diet, this regimen increased the
carotid artery pressure–diameter relationship significantly
(for example, the vessel wall compliance), whereas in MMP-
9/ mice, carotid artery compliance actually was reduced
after AngII treatment.6 Vessels from wild-type mice that
showed MMP-9 induction on AngII treatment produced
more collagen breakdown products than their MMP-9/
counterparts. These results demonstrate that (i) the onset of
AngII-induced hypertension is accompanied by increased
MMP-9 activity in conductance vessels, concurrent with a
rise in vessel distensibility; (ii) absence of MMP-9 activity
results in vessel stiffness and increased pulse pressure; (iii)
MMP-9 activation preserves vessel structure and alleviates
blood pressure increase. This suggests that, at least on the
short term, MMP activation exerts a beneficial effect by
counteracting the prohypertensive stimulus.
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The case of Alport’s syndrome: Dr Jekyll and Mr Hyde
Significant advances were recently made in understanding the
role of MMPs in the progression of renal disease by using an
animal model of Alport’s syndrome deficient in the a3 chain
of type-IV collagen (a3(IV)).7 Previous studies in humans
suggested that abnormal persistence of a1(IV) and a2(IV)
isoforms instead of a3(IV), a4(IV), and a5(IV) chains is
associated with an increased susceptibility to proteases.8
Zeisberg et al.7 confirmed that proteolysis of human as
well as mouse Alport BM was significantly enhanced
compared with normal BM, by MMP-2, MMP-3, and
MMP-9. At 4 weeks, for example, before the onset of
proteinuria in the a3(IV)/ mice, MMP-2, MMP-3, and
MMP-9 levels were significantly upregulated in glomeruli,
whereas after 8 weeks of age (when glomerular kidney disease
is established and progresses toward tubulointerstitial
fibrosis), MMP expression spread from the glomeruli into
the tubulointerstitial compartment. Genetic ablation of either
MMP-2 or MMP-9, or both, led to compensatory upregula-
tion of other MMPs in the kidney glomerulus, which most
likely accounts for the lack of aggravated phenotype in the
double-knockout MMP-9/, a3(IV)/ mice. To evaluate
the impact of type-IV collagen-degrading proteases on the
progression of kidney disease, combined pharmalogical
inhibitors of MMP-2, MMP-3, and MMP-9 were adminis-
tered orally to the a3(IV)/ mice. Pharmacological ablation
of enzymatic activity before the onset of proteinuria and
GBM structural defects led to significant attenuation in
disease progression and markedly prolonged survival. In
contrast, inhibition of MMPs after induction of proteinuria
led to acceleration of disease associated with extensive
interstitial fibrosis and early death.
These findings suggest that at early stages, MMPs help to
break down the GBM, whereas at later stages, they may help
to remove ECM associated with scarring and fibrosis. This
probably may apply to a number of pathological conditions.
MMPs and EMT: a deleterious side effect of gelatinase-
induced BM degradation
By degrading type-IV collagen, gelatinases may also aggravate
disease progression through EMT, and migration of pheno-
typically changed tubular cells through the damaged BM.
Studies on renal fibrosis indeed suggest that a third of all
disease-related fibroblasts originate from tubular epithelia at
the side of injury after unilateral ureteral obstruction,9
although this proportion may be much lower in other
pathological settings. Experimental evidence has accumulated
in favor of the implication of both MMP-2 and MMP-9 in
this process.
Cheng et al.5 showed that active MMP-2 is absolutely
required for EMT induced by TGF-b1. In addition, purified
active MMP-2 alone is sufficient to induce EMT in the
absence of exogenous TGF-b1. These results obtained in cell
culture were recently confirmed by the same group4 in mice
overexpressing constitutively active MMP-2 specifically in the
renal proximal tubule. This MMP-2 expression is sufficient to
generate the entire spectrum of pathological and functional
changes characteristic of human CKD. At the earliest point,
MMP-2 leads to structural alterations in the tubular BM, a
process that triggers tubular EMT, with resultant tubular
atrophy, fibrosis and renal failure.
A role for MMP-9 has also been established in mice with
ablation of tissue-type plasminogen activator, which actually
protects the kidney from developing interstitial fibrosis in
obstructive nephropathy.10 The pathogenic effect of tissue-
type plasminogen activator in this model primarily depends
on its ability to induce MMP-9 gene expression.
Overall, these data suggest that in conditions such as
unilateral ureter obstruction, gelatinases may aggravate
kidney disease through EMT, whereas in settings where
EMT is low, gelatinases may slow down kidney disease
progression by preventing accumulation of ECM.
Are TIMPs a factor?
Several years ago, investigators were attracted by the hypo-
thesis that changes in the activity of TIMPs, the endogenous
specific inhibitors of MMPs, could be the cause of alterations
in MMPs activity, and thus could be a factor in the
development of chronic renal disease. This hypothesis was
based on the observation that plasma and urinary concen-
trations of TIMP-1 were increased in patients with renal
disease.11 However, data from mice lacking expression of
TIMP-1 and additional human studies failed to provide a
mechanistic relevance for these initial observations. Thus,
this field of investigation remains inconclusive and given the
dual and complex role of MMPs described above, it appears,
at least at present, difficult to get better insights into the role
of TIMPs in the progression of renal disease.
Nonmatrix effects of MMPs: the picture is more complex
Matrix metalloproteinase substrates are far from being
limited to ECM components. The ability of these enzymes
to cleave biologically active peptides including cytokines and
chemokines (Table 1) can indeed override their ECM proteo-
lytic actions in some, if not many, pathological conditions.
MMP-9 can play antagonistic roles in renal inflammation
and injury. On the one hand, MMP-9 can behave as a pro-
inflammatory mediator and damage the kidney through
activation of pro-inflammatory molecules. On the other
Table 1 | Cleavage of nonmatrix substrates by MMP-9
In vitro In vivo
Plasminogen- angiostatin a1-Proteinase inhibitor
Cytokines (IL-1b, TNF-a, IL-10) Fibrin
IL-2 receptor (a chain) b1-crystallin
CXC-chemokines (IL-8, Gro-a, SDF-1, PF-4) Stem cell factor
TGF-b
Insulin, substance P
Big ET-1 - ET1
Ab amyloid peptide
Gro-a, growth regulator oncogene-a; IL, interleukin; PF-4, platelet factor-4; TGF,
tumor growth factor; TNF, tumor necrosis factor; SDF-1, stromal derived factor-1.
Italics denotes activation or induction by MMP-9.
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hand, MMP-9 can exert opposite anti-inflammatory effects
through activation of TGF-b, degradation of IL-1b, cleavage
of IL-2 receptor, and degradation of fibrin.12 MMP-9-result-
ing effects may vary from a model/pathological condition to
another. As inflammation preceeds the development of
fibrosis, the dual effect of MMPs on inflammation can
obviously impact on renal disease progression and reversal.
All the substrates of MMPs have not been discovered yet,
and the many ways in which these enzymes can influence
complex biological processes is just beginning to be unveiled.
ECM degradation products released by MMP can also have
important biological actions, as previously shown for
laminin-5 and tumstatin.3
MATRIX STABILIZATION AND PROGRESSION/REVERSAL
Tissue transglutaminase: not only glue!
Anchorage and stabilization of ECM is another step that can
eventually serve as target for therapeutic intervention. Tissue
transglutaminase-2 (TG-2) belongs to the enzymes contri-
buting to the stabilization of ECM by forming g-glutamyl-
lysine cross-linking. Its activation was detected within the
renal tissue in two experimental models of renal fibrosis
(subtotal nephrectomy and diabetic nephropathy). Subse-
quent studies observed several-fold increase of TG-2 expres-
sion in human renal biopsy samples from a range of chronic
renal diseases.13
Inhibition of TG activity may make matrix more fragile,
and thus easier to degrade. Supporting this notion, a specific
inhibitor of TG normalized glucose-induced deposition of
ECM proteins in renal proximal tubular epithelial cells.14
More recently, two chemically different TG inhibitors
prevented a decline in kidney function and reduced the
development of glomerular and tubulointerstitial fibrosis in
5/6 nephrectomy.15 This treatment reduced the exaggerated
accumulation of collagen I and III by inhibiting the
crosslinking of ECM.
Similarly, TG-2-deficient mice were protected against the
development of inflammatory and fibrotic lesions in the
unilateral ureteral obstruction model. In this case, however,
the protection was mainly due to decreased rates of TGF-b
activation that in turn reduced COLI synthesis (Sweke N.,
personal communication). Whether a similar effect can be
produced in curative protocols remains to be established.
Integrins
Integrins are ECM receptors. Expansion of mesangial matrix
and podocyte foot process effacement were attenuated in
Alport mice that were also null for integrin a1 expression.16
Monoclonal antibodies against avb6 integrin inhibited
accumulation of fibroblasts and deposition of collagen in
the interstitium of Alport mice. Transcriptomic analysis
revealed that administration of these antibodies inhibited
expression of fibrotic and inflammatory mediators induced
by the activation of TGF-b signaling pathway.17 Interestingly,
integrin b4, involved in cell–cell contact, showed differential
regulation in inflammation and fibrosis in tubulointerstitial
samples from routine kidney biopsies. In addition, clinical
follow-up revealed correlation between gene expression data
and progression of kidney disease and allowed segregation of
the biopsies into progressive or stable disease course based on
gene expression profiles.18
However, other studies revealed a different role for
integrins. Thus, integrin a1-null mice developed more severe
glomerulosclerosis than wild-type controls in the adriamycin
model of glomerular injury.19 Subsequent studies indicated
that the lack of integrin a1 was associated with activation of
the EGF receptor, which in turn induced ROS production
and excessive collagen synthesis.20
In addition to the role of integrins as stabilizers of ECM,
the intracellular integrin domain can interact with cytoske-
letal proteins through the integrin-linked kinases and activate
different signaling pathways participating in EMT and the
development of renal disease.21,22
Hyaluronan receptors
Hyaluronan is a nonsulfated glycosaminoglycan distributed
widely throughout connective and epithelial tissues. Owing
to its structural and spatial conformation, hyaluronan is
believed to participate in the formation of renal stones
(recently reviewed in ref. 23). In addition to be a component
of ECM, hyaluronan can participate in cell migration and
proliferation by interacting with a number of cell surface
receptors, mainly CD44. There is also evidence that
hyaluronan degradation products can mediate inflammation
through activation of Toll-like receptors. For these reasons,
alterations in hyaluronan synthesis and the underlying
interactions of hyaluronan with its receptors appear as
appealing hypothesis to be tested in the progression of renal
disease. Actually, hyaluronan-induced activation of Toll-like
receptor-4 was found to be an important mediator of renal
damage in an acute (ischemia/reperfusion) model of renal
epithelial damage.24 In addition, interaction between hyalur-
onan and CD44 enhanced the pro-apoptotic effect of TGF-b,
whereas genetic interruption of CD44 prevented the devel-
opment of interstitial fibrosis in the unilateral ureteral
obstruction model.25 However, these promising experimental
data were seriously challenged by a recent study in diabetic
patients. In this cohort, glomerular filtration rate, interstitial
fibrosis, and macrophages were well correlated, contrary to
hyaluronan expression that was not associated either with
macrophages or with progression of renal disease.26
Discoidin domain receptor-1
Another collagen receptor is the discoidin domain receptor-1
(DDR1). The interesting feature of DDR1 is that after the
binding of collagens, this receptor is dimerized, tyrosine
kinase is phosphorylated, and this phosphorylation leads to
P38MAP/kinase activation, making it the only known
collagen receptor displaying a direct intracellular signaling
activity.27 In addition, in vitro studies indicated that DDR1
could be a major mediator of the inflammatory response
because it is essential for the maturation and differentiation
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of monocytes to macrophages.28 To test the role of DDR1 in
the progression of renal failure, we examined the develop-
ment and the severity of renal vascular and glomerular
lesions in DDR1-null mice in the AngII-induced model of
renal disease.29 As was expected, wild-type mice developed
hypertension, perivascular inflammation, glomerular sclero-
sis, and severe proteinuria. Systolic pressure increased
similarly in the DDR1-deficient mice, but proteinuria,
glomerular fibrosis, and renal inflammation were signifi-
cantly blunted. Immunostaining for lymphocytes, macro-
phages, and abnormal accumulation of collagens I and IV
was prominent in the renal cortex of wild-type animals, but
negligible in DDR1-null mice. Interestingly, DDR1-null mice
showed a blunted response of chemokines to lipopolysac-
charide and an important degree of survival against the
lipopolysaccharide-induced mortality.
We believe that DDR1 participates in fibrosis as an
amplifier of the AngII-induced collagen synthesis. The
extracellular part of the DDR1 is responsible for binding
the collagen. Once collagen is bound, the intracellular part of
the receptor is activated and leads to induction of the
inflammatory response. Then, collagen synthesis is induced
and the collagen binding in turn increases inflammation and
so on. This positive feedback leads to the development of
fibrosis (Figure 1).
THERAPEUTIC PERSPECTIVES AND FUTURE DIRECTIONS
Is it possible to achieve temporal control of MMP’s
deleterious activities?
Matrix metalloproteinase inhibitors can be divided in three
categories: peptidomimetics, nonpeptidomimetics, and tetra-
cycline derivatives. Peptidomimetics contain a sequence that
resembles MMP substrates but are relatively nonspecific. The
nonpeptidomimetics were synthesized to resemble the
catalytic pocket of MMPs. Some of these compounds are
more selective for gelatinases and for MMP-3.
In renal diseases, MMP nonpeptidomimetic inhibitors
have recently been used in experimental models of Alport’s
syndrome7 and chronic allograft nephropathy. As in Alport’s
syndrome, inhibition of MMPs early after transplantation
reduced the development and progression of allograft
nephropathy, but promoted allograft nephropathy if initiated
at later stages.30 These findings illustrate that the major
challenge with the therapeutic interventions using MMP
inhibitors remains how to accomplish temporal and spatial
control of their activity. Given the multiple targets of MMPs,
and their variable implication depending on the stage and
etiology of the nephropathy, it is premature to predict the
therapeutic usefulness of the matrix-degrading enzymes or
their inhibitors in human renal diseases. It seems mandatory
to further unravel the pathways in which MMPs are involved
in a given nephropathy, before transferring the use of MMP
inhibitors to the renal patient.
Targeting EM stabilizers: TG, integrins, and DDR receptors
As mentioned above, the protocol of pharmacological
inhibition of TG activity was preventive and not curative. It
is important to test the efficacy of these inhibitors in curative
protocols in which CKD and abnormal ECM are already
installed. It became also recently evident that the different
subunits of the integrin superfamily have distinct and
sometimes opposite actions. In addition, their interaction
with the integrin-linked kinase signaling pathways increases
the degree of complexity and opens novel horizons for
investigation. As the use of knockout mice provided contra-
dictory results, only the development of specific inhibitors
will provide the necessary tools to verify whether targeting
integrins is an adequate strategy against CKD. Pharmacolo-
gical inhibitors for DDR1 are not available yet. As the data
from DDR1-null mice demonstrated that DDR1 are media-
tors of inflammation and fibrosis, we believe that blocking
these receptors could provide an important beneficial option
for treatment against CKD.
Identifying and targeting mediators that, similar to DDR1,
are common to proliferative, fibrogenic, and inflammatory
pathways will allow to develop therapeutic agents that would
provide a valuable assistance to ‘classical’ therapy antagoniz-
ing renin–angiotensin system to achieve regression of renal
fibrosis and reversal of renal failure. These therapies should
be started as early as possible before reaching an irreversible
(no-return) point of the decline of renal function. The search
of easily measurable markers (in urine or plasma) detecting
and predicting the evolution of renal function toward end-
stage kidney disease will be precious for the patients.
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